Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/662242


Serbia Pharmaceuticals and Healthcare Report Q4 2008


Description: Serbia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Serbia's pharmaceuticals and healthcare industry.

We calculates that the value of pharmaceuticals sold in Serbia reached US$1.17bn in 2007. Patented products accounted for almost 50% of the market (US$569mn), followed by over-the-counter (OTC) medicines (US$325mn) and generic drugs (US$279mn).

Through to 2012, we are forecasting a compound annual growth rate (CAGR) of 12.64%. According to ALiMS data, in 2007, public spending on medicines and medical care was in the region of RD145bn (EUR1.82bn), with public healthcare facilities receiving RSD135.2bn for medical services and pharmaceuticals dispensed. Primary care accounted for around 24% of the total cost, with secondary and tertiary care accounting for 48.5% of the total. Prescription pharmaceuticals dispensed to the insured represented a cost of RSD18.35bn, or some 13.57% of the total cost of healthcare insurance, or 12.72% of the total healthcare spending. Dialysis was one of the largest areas of need, with around 2.36% of the total healthcare expenditure spent on such services.

Total healthcare expenditure in Serbia was severely affected by the dissolution of Yugoslavia in the 1990s, leaving many healthcare facilities in very poor condition by the turn of the century. An EU assessment at this time found that most hospital equipment was over 20 years old and as a result it, along with several individual countries, provided funding to help improve standards. Perishable medical equipment, such as syringes, is more often than not purchased at patients' personal expense in Serbia, which has significantly constrained market growth. Additionally, most of the equipment is old and outdated, with many modern products not registered in the country.

The prescription drug market segment is dominant, illustrating the traditional reliance on hospitals and doctors as healthcare providers In 2007, prescription medicines accounted for an estimated 87.3% of the total market by value, with this figure expected to fall to just under 85% by the end of 2012. Continued pressure on prices and the encouragement of the OTC sector will be major reasons for this loss of market share.


Contents: Executive Summary
Serbia Pharmaceuticals And Healthcare Industry SWOT
Serbia Political SWOT
Serbia Economic SWOT
Serbia Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Pharmaceutical Business Environment Rankings
Limits Of Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Intellectual Property Environment
IP Disputes
Pricing Regime
Reimbursement Regime
Price Cuts
Price Rises
Industry Trends And Developments
Epidemiology
Table: Top 10 Causes Of Death In Serbia And Montenegro 20
Healthcare Sector
Table Serbia - Major General and Specialised Hospitals
Healthcare Insurance
Healthcare Reforms
Medical Tourism
Table: Cosmetic Surgery Costs
Pharmaceutical Sector
Pharmaceutical Wholesale and Retail
Domestic Pharmaceutical Industry
Domestic Company Activities
Foreign Pharmaceutical Industry
Foreign Company Activities
Table: Proposed Members Of Serbia's Pharmaceutical Industry Association
Stada Sales vs Generic Market Growth
Clinical Trials
Table: Number Of Ongoing Clinical Trials In Serbia
Medical Devices
Medical Device Classification In Serbia
Table: Serbia Medical Device Market Forecast
Industry Forecast Scenario
Overall Market Forecast
Table: Serbia - Drug Expenditure And Prescription Market Indicators, 2004-2012 (RSDmn unless otherwise stated)
Key Growth Factors – Industry
Table: Serbia - Health Expenditure Indicators, 2004-2012 (RSDmn unless otherwise stated)
Key Growth Factors – Macroeconomic
Table: Serbia - Economic Activity
Prescription Market Forecast
Table: Serbia – Prescription Market Indicators, 2004-2012 (RSDmn unless otherwise stated)
OTC Market Forecast
Table: Serbia - OTC Market Indicators, 2004-2012 (RSDmn unless otherwise stated)
Patented Market Forecast
Table: Serbia - Patented Market Indicators, 2004-2012 (RSDmn unless otherwise stated)
Generics Market Forecast
Table: Serbia - Generics Market Indicators, 2004-2012 (RSDmn unless otherwise stated)
Export/Import Forecasts
Table: Serbia – Pharmaceutical Trade Indicators, 2004-2012 (RSDmn unless otherwise stated)
Other Healthcare Data Forecasts
Table: Serbia – Other Healthcare Indicators, 2004-2012 (RSDmn unless otherwise stated)
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Table: Companies Involved In The Serbian Pharmaceutical Industry
Table: Market Share By Therapeutic Group, 2004
Table Competitive Landscape in Serbia
Table Serbia - Defined Daily Dose (DDD) per 1,000 Inhabitants
Company Monitor
Multinational Company Profiles
Pfizer
GlaxoSmithKline
Novartis
Sanofi-Aventis
Merck & Co
Indigenous Company Profiles
Hemofarm (Stada)
Galenika
Zdravlje Actavis
Jugoremedija
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Companies Mentioned Pfizer GlaxoSmithKline Novartis Sanofi-Aventis Merck & Co Hemofarm (Stada) Galenika Zdravlje Actavis Jugoremedija


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/662242

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 17/02/2012 08:03:16
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Serbia Pharmaceuticals and Healthcare Report Q4 2008
Web Address:
http://www.researchandmarkets.com/reports/662242
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €393.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 17/02/2012 08:03:16

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)